Enhancer Detail

Comprehensive information about experimentally validated enhancers

About Enhancer
Enhancer ID: E_01175
Species: Homo sapiens
Position : chr16:68362000-68362400
Year: 2022
Title: An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression.
Genome Build: hg19
Enhancer Type: Enhancer
Condition: Disease
Disease Name: hepatocellular carcinoma
PMID:  35264579
MONDO: MONDO:0007256
Tissue: liver
Tissue Ontology ID: UBERON:0002107
Cell Source: hepatocellular carcinoma cell model
Cell Type: hepatocellular carcinoma cell
Experiment Type: Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis; In vivo functional validation
High Throughput Method: ChIP-seq, RNA-seq, Hi-C
Low Throughput Method: Luciferase Reporter Assay, ChIP-RT-qPCR, CRISPR Knockout, CRISPRi, CRISPRa, qRT-PCR, Western blot, EMSA; Luciferase reporter assay; Allele-specific reporter assay; In vivo phenotyping
About Target Gene
Target gene : PRMT7
About TF
TF name : HNF4A
About Regulatory State
Regulatory State : Active
Upstream Pathway Annotation of TF
GeneName Pathway Name Source Gene Number
HNF4A FOXA2 and FOXA3 transcription factor networks pid 45
HNF4A HIF-1-alpha transcription factor network pid 67
HNF4A Nuclear Receptor transcription pathway reactome 51
HNF4A Regulation of gene expression in beta cells reactome 17
HNF4A Regulation of nuclear SMAD2/3 signaling pid 82
HNF4A TGF_beta_Receptor netpath 220
HNF4A Maturity onset diabetes of the young kegg 25
Enhancer Associated Network
Overlapping Enhancers (hg19)
No overlapping enhancers found in hg19 at this locus.
Expression of Target Genes for the Enhancer